Hanson Wade have taken the decision to cancel this meeting.
Please do accept our apologies for any inconvenience or disappointment this will cause.

Please register your interest here if you would like updates on the meeting or topic.

PI3K Homepage (2)

Welcome to the PI3K Pathways Digital Summit

With 4 currently approved PI3K inhibitors in the market, and countless investments, M&As and candidates entering the clinical stages, the PI3K pathways space has experienced significant growth in recent years.

The PI3K Pathways Digital Summit is the industry’s only meeting dedicated to overcoming the challenges in developing clinically effective next generation PI3K inhibitors.

Join the online discussion at the only digital platform dedicated to bringing together the community of PI3K experts from large pharma, innovative biotech and research institutes for a unique opportunity to address the challenges of the PI3K and AKT pathway, gain clarity on the mTOR signalling pathway and participate in cross-disciplinary discussions with fellow industry peers.

Bespoke Virtual Platform - How Does It Work?

World-Class Speaker Faculty

James Garner

Chief Executive Officer & Managing Director

Kazia therapeutics

Ningshu Liu

Head of Laboratory Immuno Oncology & Senior Director & Global Strategy Lead


Nishan Rajakumaraswamy

Director Clinical Research Oncology/ Hematology

Gilead Sciences

Zoe Johnson

Chief Scientific Officer


Christian Ottensmeier

Professor - Experimental Cancer Medicine

University of Southampton

Emmanuel Normant

Vice President - Preclinical Sciences

TG Therapeutics

Ralitsa Madsen

Research Fellow

University College London

William Kerr

Chief Scientific Officer

Alterna Therapeutics